Skip to main content

Frontier Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

BOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced that Chris Varma, Ph.D., co-founder, chair, and chief executive officer of Frontier Medicines, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:30 p.m. PST.

About Frontier Medicines
Frontier Medicines is a clinical-stage precision medicine company pioneering groundbreaking medicines to transform treatment for genetically defined patient populations, starting with oncology and immunology. Our proprietary chemoproteomics-powered drug discovery engine, the Frontier™ Platform, leverages covalent chemistry and machine learning to unlock difficult-to-drug, disease-causing proteins for drug development. Today, we are advancing a diversified pipeline of wholly owned precision medicines against the most critical drivers of cancer and high-value immunology programs. For more information, please visit www.frontiermeds.com. Follow Frontier on LinkedIn.

Media Contact
pr@frontiermeds.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  221.25
+7.48 (3.50%)
AAPL  258.90
+5.40 (2.13%)
AMD  231.82
+10.29 (4.64%)
BAC  51.88
+1.60 (3.18%)
GOOG  314.74
+10.81 (3.56%)
META  612.42
+37.37 (6.50%)
MSFT  374.33
+2.04 (0.55%)
NVDA  182.05
+3.95 (2.22%)
ORCL  143.66
+0.49 (0.34%)
TSLA  343.25
-3.40 (-0.98%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.